Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Share
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
DexCom (DXCM) Q4 2024 Earnings Call Transcript
PBF Energy posts third consecutive quarterly loss on falling margins
US sanctions strand Iran, Russia oil on tankers, driving up crude costs
Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
View Options
Source link
DexCom (DXCM) Q4 2024 Earnings Call Transcript
PBF Energy posts third consecutive quarterly loss on falling margins
US sanctions strand Iran, Russia oil on tankers, driving up crude costs
Insurer Humana forecasts annual profit below estimates